Michail Shipitsin, Ph.D., is VP, Biomarker Development at Acrivon Therapeutics, Inc. Michail has over 15 years of experience in translational and biomarker research and development. Previously, he headed biomarker development at Xtuit Pharmaceuticals with a focus on NASH liver disease and cancer. After joining the biotech industry, Michail led development of a first in kind multiplex immunofluorescence prognostic test for prostate cancer at Metamark Genetics.
Michail earned his Diploma in Molecular Biology from Novosibirsk State University. He completed Ph.D. in Biochemistry from Tufts University and conducted postdoctoral studies at Dana-Farber Cancer Institute with a focus on biomarkers in breast cancer.